Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways

Mapelli, Massimo; Mattavelli, Irene; Salvioni, Elisabetta; Bonomi, Alice; Capra, Nicolò; Palermo, Pietro; Banfi, Cristina; Paolillo, Stefania; Biondi, Maria Luisa; Agostoni, Piergiuseppe

doi:10.1007/s40268-023-00438-2

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown improvements in the objective exercise capacity and tolerance measures of patients with symptomatic HF after the sacubitril/valsartan initiation (23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Palau et al (23) and Vitale et al (24) showed improvements in the peak VO 2 and VE/VCO 2 slope in HFrEF patients after follow-up durations between 1 and 6 months after the sacubitril/ valsartan initiation (i.e., the peak VO 2 improved from 14.6 ± 3.3 to 17.2 ± 4.7 ml/kg/min; p < 0.0001, and the VE/VCO 2 slope decreased from 34.1 ± 6.3 to 31.7 ± 6.1; p = 0.006).…”

Section: Discussionmentioning

confidence: 99%

Effects of sacubitril/valsartan on the functional capacity of real-world patients in Italy: the REAL.IT study on heart failure with reduced ejection fraction

Sarullo,

Nugara,

Sarullo

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundHeart failure (HF) significantly affects the morbidity, mortality, and quality of life of patients. New therapeutic strategies aim to improve the functional capacity and quality of life of patients while controlling HF-related risks. Real-world data on both the functional and cardiopulmonary exercise capacities of patients with HF with reduced ejection fraction upon sacubitril/valsartan use are lacking.MethodsA multicenter, retrospective, cohort study, called REAL.IT, was performed based on the data collected from the electronic medical records of nine specialized HF centers in Italy. Cardiopulmonary exercise testing was performed at baseline and after 12 months of sacubitril/valsartan therapy, monitoring carbon dioxide production (VCO2) and oxygen consumption (VO2).ResultsThe functional capacities of 170 patients were evaluated. The most common comorbidities were hypertension and diabetes (i.e., 53.5 and 32.4%, respectively). At follow-up, both the VO2 peak (from 15.1 ± 3.7 ml/kg/min at baseline to 17.6 ± 4.7 ml/kg/min at follow-up, p < 0.0001) and the predicted % VO2 peak (from 55.5 ± 14.1 to 65.5 ± 16.9, p < 0.0001) significantly increased from baseline. The VO2 at the anaerobic threshold (AT-VO2) increased from 11.5 ± 2.6 to 12.5 ± 3.3 ml/kg/min (p = 0.021), and the rate ratio between the oxygen uptake and the change in work (ΔVO2/Δwork slope) improved from 9.1 ± 1.5 to 9.9 ± 1.6 ml/min/W (p < 0.0001).ConclusionsSacubitril/valsartan improves the cardiopulmonary capacity of patients with HFrEF in daily clinical practice in Italy.

show abstract